The Medicines Company, Alnylam Announce Advance Development Candidate for Treatment of Hypercholesterolemia

The Medicines Company MDCO and Alnylam Pharmaceuticals, Inc. ALNY announced today that their strategic alliance has yielded a lead Development Candidate that is a subcutaneously administered RNAi therapeutic (ALN-PCSsc) targeting PCSK9 for the potential treatment of hypercholesterolemia. New data from non-human primate studies were presented at the Oligonucleotide Therapeutics Society (OTS) meeting, and show that ALN-PCSsc leads to an up to a 90% PCSK9 knockdown and an up to 68% lowering of LDL cholesterol in the absence of statins. PCSK9 is a protein that regulates low-density lipoprotein (LDL) receptor levels See full press release